Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Inbiose N V has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 6 distinct examiners and 3 distinct art units, indicating a portfolio with broad examination coverage. That spread can create different procedural and substantive patterns across applications, even where the underlying biotechnology subject matter is related.
EIX, EMILY FAY is the busiest examiner, with 2 pending matters. The assignment represents a meaningful focal point, but it does not encompass the entire pending portfolio. Counsel should coordinate recurring claim terminology and disclosure positions across the examiner and art-unit assignments while preserving application-specific responses to prior art and written-description issues.
The data supports active docket segmentation by examiner and art unit. A portfolio review should identify shared technical themes, then distinguish the arguments that depend on each application’s record. This approach can reduce inconsistent prosecution positions without assuming that one examiner’s treatment will apply across all pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPANGLER, JOSEPH RANKIN | 2 | 40.8% | +70.6% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| MCKNIGHT, CIARA A | 1 | 61.5% | +40.3% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904189 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | SPANGLER, JOSEPH RANKIN | 6d |
| 18579664 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | JONES-FOSTER, ERICA NICOLE | — |
| 18041019 | METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION | MONSHIPOURI, MARYAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904189 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | SPANGLER, JOSEPH RANKIN | 6d |
| 17627088 | PRODUCTION OF FUCOSYLLACTOSE IN HOST CELLS | HOLLAND, PAUL J | 26d |
| 18579664 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | JONES-FOSTER, ERICA NICOLE | — |
| 18041154 | CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES | MCKNIGHT, CIARA A | — |
| 18041064 | PRODUCTION OF OLIGOSACCHARIDE MIXTURES BY A CELL | EIX, EMILY FAY | — |
| 18041019 | METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION | MONSHIPOURI, MARYAM | — |
| 17295688 | PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING ALPHA-1,3-FUCOSYLTRANSFERASE ENZYMES | SPANGLER, JOSEPH RANKIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 5 |
| 1653 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579664 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | JONES-FOSTER, ERICA NICOLE | 1656 | §102§112 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18041154 | CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES | MCKNIGHT, CIARA A | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18041064 | PRODUCTION OF OLIGOSACCHARIDE MIXTURES BY A CELL | EIX, EMILY FAY | 1653 | §103 | Non-Final OA | — | Pending | Feb 08, 2023 |
| 18041019 | METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION | MONSHIPOURI, MARYAM | 1651 | §103§112Other | Non-Final OA | — | Pending | Feb 08, 2023 |
| 17904189 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | SPANGLER, JOSEPH RANKIN | 1656 | §101§102§112Other | Non-Final OA | 6d | Pending | Aug 12, 2022 |
| 17627088 | PRODUCTION OF FUCOSYLLACTOSE IN HOST CELLS | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | 26d | Pending | Jan 13, 2022 |
| 17295688 | PRODUCTION OF 3-FUCOSYLLACTOSE AND LACTOSE CONVERTING ALPHA-1,3-FUCOSYLTRANSFERASE ENZYMES | SPANGLER, JOSEPH RANKIN | 1656 | §103Other | Final Rejection | — | Pending | May 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInbiose N V has 7 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Joseph Rankin Spangler has the most, with 2 of Inbiose N V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
